27 May 2024
27 May 2024
The clinical-stage biotech will share preliminary safety and efficacy data with its ADC at the 2024 ASCO meeting.
The speed and flexibility required in clinical trials for COVID-19 set a new precedent for what can be achieved in fighting infectious diseases. From collaborative digital platforms to utilizing AI, GlobalData examines some of the key trends affecting contract research organizations (CROs).
MSD licenced the antibody-drug conjugate (ADC) therapy, sacituzumab tirumotecan, from China-based Sichuan Kelun-Biotech in 2022.
The NHS has set an ambition to eliminate cervical cancer by 2040 and the effectiveness of the HPV vaccine will be the key component of this elimination strategy.
The approval is based on robust clinical evidence, including findings from a global Phase III clinical trial.
Paolo Morgese, vice president of European public affairs at the Alliance for Regenerative Medicine, discusses the barriers affecting access to gene therapies.
The extended Series B funding surge propels the total Series B capital to $99m.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report is the 14th edition offering an analysis of the CMO industry, using the FDA’s NDA approvals as the primary indicator of performance. The report is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs. This year’s edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
GlobalData's latest report is the 14th edition offering an analysis of the CMO industry, using the FDA’s NDA approvals as the primary indicator of performance. The report is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs. This year’s edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
GlobalData's latest report is the 14th edition offering an analysis of the CMO industry, using the FDA’s NDA approvals as the primary indicator of performance. The report is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs. This year’s edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
Give your business an edge with our leading industry insights.
